NOC - Northrop Grumman Corp
Executive Summary
Northrop Grumman Corporation is a US prime defence contractor operating across four principal areas: aeronautics, mission systems, defence systems, and space systems. It supplies the US Department of Defense, the intelligence community, allied governments, and select commercial customers with platforms and services spanning strategic bombers (B-21 Raider), ICBM modernisation (Sentinel), missile defence interceptors, and classified space payloads. Within the US defence industrial base it holds a leading position in strategic deterrence and a near-monopoly position on the ground-based midcourse segment of the US missile defence architecture.
The investment case requires three things to go right. First, production ramp on the recent USD 3 billion missile interceptor award must convert into recognised revenue without programme disruption. Second, the company needs to sustain its recent pattern of earnings beats and continue raising guidance off a record backlog, with Q3 2026 results as the next key catalyst. Third, the B-21 Raider and Sentinel ICBM programmes must remain funded at or above current run-rates through the next US defence budget cycle. The primary risk is the heavy concentration on a single US government customer disclosed in the 10-K, which leaves the equity exposed to potential contract terminations or continuing-resolution funding shortfalls.
BUY. Conviction Score: 68/100. The view would move toward a downgrade on a confirmed Sentinel cost overrun triggering a Nunn-McCurdy breach, a multi-quarter EPS miss against consensus, or any disclosure of a contract cancellation on a top-five backlog programme.
Bottom line - BUY at 68/100.
Thesis break: A confirmed Nunn-McCurdy cost breach on the Sentinel ICBM programme, a US Department of Defense cancellation of the B-21 Raider programme, or two consecutive quarters of EPS misses of more than 5% against consensus would invalidate the investment thesis regardless of share price.
Business Model
Northrop Grumman generates revenue predominantly through long-cycle US government contracts, with sales to the US Department of Defense and the broader US government comprising the overwhelming majority of top line. The mix spans cost-plus and fixed-price production contracts, sustainment and modernisation programmes, and classified research and development. Recent reported revenue (Q1 2026) reached USD 9.88 billion, up 4.4% year-on-year, consistent with the company's stated longer-run annual revenue run-rate of roughly USD 42 billion implied by recent disclosures. The contract structure is overwhelmingly backlog-funded, with a record backlog disclosed in the most recent reporting period supporting the company's decision to raise 2026 guidance.
The competitive moat rests on programme incumbency and capital intensity of the underlying platforms. Northrop Grumman is the sole-source prime on B-21 Raider, the integrating contractor on Sentinel, and a near-exclusive supplier of next-generation missile defence interceptors funded through the Missile Defense Agency. These positions are protected by patent: extremely long certification and qualification cycles, classified supply chains, and US-government-imposed barriers to foreign ownership of critical defence suppliers. Margins are structurally lower than commercial aerospace peers but more durable given the mission-critical nature of the work and the limited number of qualified primes in each domain.
Capital allocation is conservative and aligned with defence primes. The company has historically prioritised dividends and selective share repurchases over large transformative M&A, which suits a backlog-heavy business model where organic execution is rewarded more than portfolio reshuffling. Modest insider activity in the May 2026 window (a small director sale of 95 shares disclosed via Form 4) is immaterial in scale and does not change the fundamental picture. Reported P/E of 15.19 against a 1-year target price of USD 639 implies the equity is trading at a discount to sell-side expectations and to where it has historically de-rated.
Financial Snapshot
Recent Catalysts
[May 2026] - On 4 May 2026, director Mark A. Welsh III disclosed the sale of 95 shares of Northrop Grumman common stock via a Form 4 filing; the transaction is immaterial in size relative to shares outstanding and reflects routine insider activity rather than a directional signal. Source: GuruFocus.
[May 2026] - On 1 May 2026, Northrop Grumman announced its 2026 Supplier Excellence Awards, recognising more than 30 domestic and international suppliers across its aeronautics, mission systems, defence systems, and space systems businesses. Source: Northrop Grumman Newsroom.
[Q1 2026] - Northrop Grumman reported Q1 2026 net sales of USD 9.88 billion, a 4.4% year-on-year increase, alongside an earnings release, webcast, and 10-Q filing dated 21 April 2026 and a transcript dated 14 April 2026. Source: Northrop Grumman Investor Relations.
[Q1 2026] - Northrop Grumman raised full-year 2026 guidance on the back of its record backlog and recent contract awards, including a USD 3 billion missile interceptor production agreement. Source: Northrop Grumman Investor Relations / earnings disclosure.
[December 2025] - Zacks Research raised its earnings estimate for Northrop Grumman in late December 2025, reflecting improving expectations ahead of subsequent guidance actions. Source: Defense World / Zacks Research.
Thesis Evaluation
Bull Case (37% weight)
The company sustains its current pattern of contract-driven backlog conversion, B-21 and Sentinel production ramp on schedule, and the USD 3 billion missile interceptor award translates into multi-year revenue at attractive long-run margins. Re-rating to a target of $640 within 12 months as the backlog-to-revenue ratio supports a return toward historical defence prime multiples. The 1-year sell-side target of USD 639 aligns with this scenario and embeds the upside from continued guidance raises.
Base Case (47% weight)
Backlog grants convert into reported revenue at a pace consistent with the 4.4% Q1 2026 growth print, margins remain in line with recent disclosures, and the next earnings release confirms guidance is intact without a further raise. EPS follows the consensus path implied by the current P/E of 15.19 and recent history of reported earnings beats. A target of $560 within 12 months reflects mid-single-digit revenue growth and modest multiple expansion as the backlog visibility is priced in.
Bear Case (16% weight)
A continuing resolution or budget disruption delays B-21 or Sentinel funding, a Nunn-McCurdy-style cost breach on a major programme triggers restructuring charges, or a single US government customer action cancels a top-five backlog programme. Reported EPS declines as flagged in the Q3 2026 setup, and the multiple contracts as US revenue concentration is repriced. A target of $420 within 12 months, materially below current levels, with the 52-week low of USD 470.06 acting as near-term technical support.
Key Risks
- US Government Customer Concentration: The company derives the overwhelming majority of revenue from a single US government customer, and a contract cancellation, continuing-resolution funding shortfall, or programme cancellation on a top-five backlog item could remove years of forward earnings. Estimated probability: 25%. Impact: severe.
- Sentinel ICBM Cost Overrun: The Sentinel ICBM modernisation programme is large and schedule-sensitive; a Nunn-McCurdy breach or material restructuring would trigger non-cash charges and programme repricing. Estimated probability: 15%. Impact: severe.
- Q3 2026 EPS Decline: Recent sell-side commentary and the research notes flag an expected Q3 2026 EPS decline relative to the prior-year period, which would test the consensus revenue and earnings beat pattern. Estimated probability: 40%. Impact: moderate.
- Fixed-Price Contract Margin Compression: A meaningful share of revenue runs through fixed-price production contracts; cost inflation, supply chain issues, or supplier disruptions could compress segment margins below historical averages. Estimated probability: 30%. Impact: moderate.
- Defence Budget and Sequestration Risk: Any return to budget caps, full-year continuing resolutions, or sequestration under future US fiscal policy could delay obligations on backlog-funded programmes and shift the revenue curve to the right. Estimated probability: 20%. Impact: moderate.
- Valuation Re-rating Downside: The current P/E of 15.19 sits below the 52-week high implied multiple; if the backlog conversion thesis stalls, the equity could de-rate toward historical trough multiples. Estimated probability: 25%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: Long-term, defence-sector-tolerant investors with a minimum holding period of three to five years, comfortable with US-government revenue concentration, and seeking exposure to strategic deterrence and space systems franchises. Suitable for income-oriented portfolios given the established dividend history and for growth-tilted portfolios where the backlog conversion story can compound through programme cycles.
Avoid if: Investors with a mandate to limit single-customer concentration below 50% of revenue, those unable to tolerate binary programme-event risk on classified contracts, or short-horizon traders looking for catalysts within a single quarter. Speculative capital that requires rapid re-rating or has low tolerance for continuing-resolution-driven drawdowns should also avoid this name.
Recommendation
BUY - 68/100. The recommendation is BUY today because contract momentum, a record backlog, and recent guidance raises outweigh the near-term EPS softness flagged into Q3 2026 and the RBC downgrade, with the valuation at a P/E of 15.19 against a USD 639 1-year target providing a margin of safety. An upgrade to a higher tier would require sustained multi-quarter revenue acceleration, a clean Sentinel review, and a confirmation that the recent EPS decline was transitory rather than structural. A downgrade would be triggered by a confirmed major programme cancellation, a Nunn-McCurdy breach on Sentinel, or two consecutive quarters of EPS misses against consensus. At the current price of $549.13 the shares trade above our buy ceiling of $466.67: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $567.20, 3% above the current price of $549.13 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $466.67 - below this level the upside to the base-case target ($560.00) is at least 2x the downside to the bear case ($420.00), the minimum risk/reward we require before committing new capital.
between $466.67 and $560.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $560.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 37%.
if A confirmed Nunn-McCurdy cost breach on the Sentinel ICBM programme, a US Department of Defense cancellation of the B-21 Raider programme, or two consecutive quarters of EPS misses of more than 5% against consensus would invalidate the investment thesis regardless of share price, regardless of price - the bear target of $420.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 68/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 68 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Coverage was drawn from public news flow including company earnings releases and presentations, regulatory filings, investor relations materials, and third-party web research across financial news wires and analyst commentary. Sentiment was characterised from observable public reporting rather than aggregated commentary.
Primary source types: SEC filings (Form 10-K, Form 10-Q, Form 4 insider disclosures), company press releases via the Northrop Grumman Newsroom, Northrop Grumman Investor Relations disclosures, company earnings call transcripts and webcasts, and regulatory announcements sourced from US defence and aerospace news outlets.
Key sources
- Northrop Grumman (NOC) Earnings Date and Reports 2026 $NOC
- Northrop Grumman (NOC) Q4 2025 Earnings Transcript | The Motley Fool
- Northrop Grumman's Q3 2026 Earnings: What to Expect
- Northrop Grumman (NOC) Shares Slip After RBC Downgrade Amid Dividend Sustainability Focus
- Northrop Grumman Corporation (NOC) Stock Price, News, Quote & History - Yahoo Finance
- Northrop Grumman Corporation (NOC) Stock Price, Quote, News & Analysis | Seeking Alpha
- Northrop Grumman (NOC) Q1 2026 Earnings: Results, Market Reaction & History | 24/7 Wall St.
- Northrop Grumman (NYSE: NOC) lifts 2026 guidance after record $105B backlog
- Northrop Grumman Enters Into $3 Billion Landmark Agreements to Accelerate Missile Interceptor Production - Northrop Grumman
- Northrop Grumman Enters Into $3 Billion Landmark Agreements to Accelerate Missile Interceptor Production | Northrop Grumman
Analysis generated 2026-10-04. Market data as of 2026-11-12.